 |
Depósito mínimo $50 Promoción exclusiva |
Nuestra puntuación |
Comisión 0% |
Are you looking to buy IonPharmaceuticals stocks? Chech our Reportlab with an in-depth review, check prices, statistics and see if buying this stock is interesting right now. This article will help you buy NASDAQ:IONS! and analyze the company to see if this stock might be an interesting option to invest in. We will enlighten you about IonPharmaceuticals stocks and how to buy and use them. Click on the button to start reading the review right now or scroll down for real time statistics about this company.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington’s diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer’s diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson’s disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with AstraZeneca; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Volumen medio
934,938 shs
TAPA DEL MERCADO
$8.42 billion
Bolsa
NASDAQ
¡Compre esta acción!
|
NOMBRE
|
TICKER
|
INDUSTRIA
|
SECTOR
|
VOLUMEN
|
COMPRE ESTA ACCIÓN AHORA
|
|---|---|---|---|---|---|
|
NASDAQ:IONS
|
Preparados farmacéuticos
|
Médico
|
12,480 shs
|
Below is a quick guide on how to buy NASDAQ:IONS stocks safe, fast and around the world in less than five minutes.
Paso 1: Abrir una cuenta en eToro – eToro is the best broker to buy IonPharmaceuticals shares in the world as you won’t pay any commissions. To do this, visit the eToro website and open an account, it is 100% safe and they offer a huge amount of stocks.
Paso 2: Suba su identificación - Según las regulaciones de KYC, eToro le pedirá que suba una copia de su pasaporte o licencia de conducir.
Paso 3: Depositar los fondos - Deposite algo de dinero en su recién creada cuenta de eToro. Puede elegir entre transferencia bancaria, monedero electrónico o tarjeta de débito/crédito o Paypal.
Paso 4: Buy IonPharmaceuticals – Search for “”NASDAQ:IONS”” and click on the “”Trade”” button. Enter the total amount of your investment (minimum $50) and confirm the order by clicking the “”Open Trade”” button. And that’s it: you have just bought IonPharmaceuticals stocks with 0% commission!.
1 | | Depósito mínimo $50 Promoción exclusiva | Nuestra puntuación 10 ★★★★★ | Comisión 0% |
13 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
Wall Street analysts have given Ionis Pharmaceuticals a “Hold” rating, but there may be better short-term opportunities in the market. Some of Reportlab’s past winning trading ideas have resulted in 5-15% weekly gains. Reportlab just released five new trading ideas, but Ionis Pharmaceuticals wasn’t one of them. Reportlab thinks five stocks may be even better buys in the how to buy stocks guide.
1 | | Depósito mínimo $50 Promoción exclusiva | Nuestra puntuación 10 ★★★★★ | Comisión 0% |
2 |  | Depósito mínimo $50 Promoción exclusiva | Nuestra puntuación 10 ★★★★★ | Comisión 0% |
3 |  | Depósito mínimo $50 Promoción exclusiva | Nuestra puntuación 10 ★★★★★ | Comisión 0% |
It can be difficult to navigate through all the outdated and incorrect information related to purchasing NASDAQ:IONS stocks. We believe that stocks should be accessible for all, which is why we’ve created this handy guide on where to buy IonPharmaceuticals stocks with a step by step approach.
You’ll need to register with a broker, in these times you can’t go without once and it’s crucial to use a regulated broker that’s allowed to operate there, otherwise, you risk losing funds. eToro is one such broker, and one of the best brokers to buy IonPharmaceuticals stocks with 0% comission, to sign up just click on open account in the following table or compare other options.
Debido a que eToro es una plataforma regulada, tendrá que completar el proceso KYC, esto es una práctica estándar y sólo toma un par de minutos. Tendrá que proporcionar un documento de identidad con fotografía (pasaporte, permiso de conducir) y un comprobante de domicilio (factura de servicios públicos, extracto bancario).
Una vez que se haya registrado y verificado su cuenta, deberá depositar fondos. eToro acepta tarjetas de crédito/débito, transferencias bancarias y también monederos electrónicos. Así que, sea cual sea su preferencia, habrá algo para usted.
Now that you’ve funded your eToro account, just type “NASDAQ:IONS stocks" en la barra de búsqueda de la parte superior de la pantalla y pulse "comercio".
All that’s left is to buy some NASDAQ:IONS stock. Simply enter the amount you want to purchase and hit the “buy” button. The amount you bought will be automatically credited to your account where you can monitor its performance.
All in all, NASDAQ:IONS is an incredibly interesting company that has the potential to solve some major issues in the business space. After reading this guide you should know how to buy this investment using the best broker or platform. We recommend eToro to anyone looking for a regulated, easy-to-use, fully-featured broker to buy IonPharmaceuticals stocks. As with any broker or online platform, it’s crucial you set up 2FA when using their tools as it ensures your funds are completely safe.
Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Ionis Pharmaceuticals.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its earnings results on Wednesday, November, 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.11. The company earned $160 million during the quarter, compared to analysts’ expectations of $182.14 million. Ionis Pharmaceuticals had a net margin of 7.82% and a trailing twelve-month return on equity of 6.57%. The firm’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 earnings per share.
View Ionis Pharmaceuticals’ earnings history.
Ionis Pharmaceuticals’ stock was trading at $49.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IONS stock has increased by 21.8% and is now trading at $59.84.
13 equities research analysts have issued 12 month price targets for Ionis Pharmaceuticals’ shares. Their forecasts range from $34.00 to $91.00. On average, they anticipate Ionis Pharmaceuticals’ share price to reach $62.80 in the next year. This suggests a possible upside of 4.9% from the stock’s current price.
View analysts’ price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.
Launched in 2006, eToro is, in our opinion, without a doubt the best broker for buying NASDAQ:IONS stocks in the world. The onboarding process is simple, it’s designed to make sure even those new to the stock market are ready to start investing the shortest amount of time possible. As a regulated platform you gain several benefits, most importantly, you know they’re not going to run off with your hard-earned money./
Más de 95% de los fondos de los clientes se mantienen fuera de línea, en almacenamiento en frío, lo que es crucial para cualquier corredor que gestione sus activos. Independientemente de lo segura que sea una plataforma, le recomendamos que utilice el sistema 2FA para añadir una capa adicional de seguridad a su cuenta.
eToro ofrece a los usuarios una serie de características para empezar a invertir lo antes posible. Tienen una característica relativamente única llamada copy trading, que le permite obtener un ingreso pasivo al imitar a operadores experimentados, esto le permite comenzar a obtener ganancias rápidamente, y le da una mejor comprensión de las estrategias utilizadas por los profesionales. Además, eToro permite a los usuarios invertir en carteras gestionadas, siendo una cartera gestionada una variedad de activos similares agrupados, lo que le permite diversificar su cuenta, reduciendo cualquier riesgo potencial. Para aquellos con experiencia previa en operaciones, puede invertir en mercados fuera de las acciones, ya que eToro permite a los usuarios operar con ETFs, materias primas, cripto e índices. Si ya invierte fuera del espacio bursátil, esto puede ser muy útil, ya que le permite gestionar todas sus inversiones en un solo lugar.
Ionis Pharmaceuticals’ management team includes the following people:
Dr. Stanley T. Crooke, Founder & Exec. Chairman (Age 76, Pay $1.97M)
Dr. Brett P. Monia, Founder, CEO & Director (Age 60, Pay $1.06M)
Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 59, Pay $834.19k)
Mr. Patrick R. O’Neil, Exec. VP of Legal, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 47, Pay $816.23k)
Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 67, Pay $1.36M)
Dr. Richard S. Geary, Exec. VP & Chief Devel. Officer (Age 63, Pay $829.79k)
Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 64)
Mr. D. Wade Walke, VP of Investor Relations
Ms. Roslyn Patterson M.B.A., VP of Marketing & Communications
Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of IONS’s competitors.
Los CFD son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento. 68% de las cuentas de inversores minoristas pierden dinero al operar con CFDs con este proveedor. Debe considerar si entiende cómo funcionan los CFD y si puede permitirse asumir el alto riesgo de perder su dinero.
Based on aggregate information from Reportlab watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol “IONS.”
Ionis Pharmaceuticals’ stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (14.97%), First Trust Advisors LP (0.99%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Pinnacle Associates Ltd. (0.40%), Swiss National Bank (0.36%) and Dowling & Yahnke LLC (0.34%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O’neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.
IONS stock was sold by a variety of institutional investors in the last quarter, including Dowling & Yahnke LLC, AJO LP, Pinnacle Associates Ltd., BLB&B Advisors LLC, Sicart Associates LLC, Zurcher Kantonalbank Zurich Cantonalbank , Swiss National Bank, and First Trust Advisors LP. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Joseph Klein III, Patrick R O’neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.
1 | | Depósito mínimo $50 Promoción exclusiva | Nuestra puntuación 10 ★★★★★ | Comisión 0% |
IONS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Nisa Investment Advisors LLC, Sumitomo Mitsui Trust Holdings Inc., State of Wisconsin Investment Board, Castle Rock Wealth Management LLC, Victory Capital Management Inc., DNB Asset Management AS, and California Public Employees Retirement System.
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the stock market include Revisión de Interactive Brokers, Revisión de eToro, Revisión de DEGiro, Revisión de AvaTrade, Revisión de IG Markets, Revisión de los mercados IC, Revisión de CMC Markets, Revisión de Admiral Markets y muchos más. Lea una de las reseñas para saber todo sobre el corredor y comience a comprar acciones ahora.
One share of IONS stock can currently be purchased for approximately $59.84.
Ionis Pharmaceuticals has a market capitalization of $8.37 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis.
Ionis Pharmaceuticals employs 817 workers across the globe.
The official website for Ionis Pharmaceuticals is www.ionispharma.com.
En Reportlab.org queremos asegurarnos de que tenga toda la información más relevante sobre compra de acciones. Le ofrecemos las mejores guías sobre el mercado de valores con reseñas personales, información de fondo, reseñas de las plataformas, instrucciones y mucho más. ¿Quiere obtener otra información? Entonces consulte la Acciones OTC, Acciones del NASDAQ, Acciones de la Bolsa de Valores de Nueva York, Acciones LON, Acciones de la FRA, Acciones ETR, Reservas de la EPA, Acciones del TSX o Acciones Amex. Buscando información más detallada como 5g de existencias, acciones de biotecnología, acciones de oro y otra información de nuestro laboratorio de informes.
How can you buy IonPharmaceuticals stock on the internet?
You can easily buy IonPharmaceuticals stocks with one of the well known regulated brokers on the internet. You can open an account within 5 minutes, make deposits with countless payment providers and trade with professional tools on their platform. At the moment, our visitors rate eToro as the most popular choice.
Otra opción es utilizar un corredor regulado como Mercados IC o Corredores de bolsa interactivos. You can an account with these brokers and start buying or trading NASDAQ:IONS stocks in a safe and complete environment to trade in.
Where to buy IonPharmaceuticals stock?
You will first want to find a licensed broker that supports NASDAQ:IONS stock. One of our favourite brokers, eToro for example, allows you to make investments into this asset from just $25 and only charges you the spread. Another option is using a regulated broker like DEGIRO or Interactive Brokers. You can open an account with these brokers and start buying or trading NASDAQ:IONS stocks in a safe and complete environment.
Is NASDAQ:IONS stock a good investment?
As with any other asset, there is an element of risk associated with buying NASDAQ:IONS stocks. Therefore, you will want to study the market and make a decision based on your financial standing and the risk you are willing to take.
Is IonPharmaceuticals stock safe to invest in?
All stocks are volatile, or affected by market circumstances. The case with NASDAQ:IONS is no different, with its price fluctuating dramatically within short periods. As such, if the market goes against you, then you will end up facing a loss. We advice you to do research first before investing in IonPharmaceuticals stock.
How do you trade IonPharmaceuticals stocks?
You can trade stocks by first opening an account with a regulated platform and making a deposit in US dollars, EUROs or other currency. Next, search for IonPharmaceuticals stock and choose from a buy or sell order – depending on whether you think the stock asset will rise or fall in value. If you speculated on NASDAQ:IONS stocks correctly, you will have made a profit. The size of your trading profit will ultimately be determined by your stake and at what percentage your position grew.
How to sell IonPharmaceuticals stock?
To sell your NASDAQ:IONS stocks investment, you can sign in to your broker account and cash out directly from within your portfolio. If you have stored the stocks elsewhere, you will first have to transfer them to a third-party provider or broker to cash out.
What is the best IonPharmaceuticals stock trading platform?
eToro, is a top-rated platform for beginners, albeit, it charges significantly lower fees. For example, there are no fees to deposit with a debit/credit card and you only need to cover the spread when trading NASDAQ:IONS stock.
Stephen sabe mucho sobre productos financieros y, en particular, tiene una gran pasión por los mercados de valores y sus participantes. Esperamos que la información proporcionada le sirva de ayuda. ¿Hay algo que no está claro? Deje sus preguntas o comentarios al final de la página.
| Nuestra puntuación ★★★★★ | |
| Nuestra puntuación ★★★★★ | |
| Nuestra puntuación ★★★★★ |
Boletín de noticias
Noticias recientes
| |
Nuestra puntuación |
Comisión 0% |
Datos de acciones y criptografía en tiempo real
Notificaciones, consejos y noticias
Las mejores guías sobre acciones y criptografía
Reseñas sobre el corredor y la bolsa en línea
Reportlab Finanzas es una página web puramente informativa y en ningún caso implica un asesoramiento de inversión. Todas las inversiones conllevan riesgos y usted puede perder todas sus inversiones. No invierta dinero que no pueda permitirse perder.
Reportlab Finanzas
38 Holburn Lane
Heckfield Green
IP21 0UB
Reino Unido
Copyright © 2022 Reportlab.Finance | Todos los derechos reservados.
